Tirzepatide, sold under the brand Mounjaro, was studied in people without diabetes in three doses of 5, 10, and 15 milligrams. Obese participants or overweight participants who took a dose of 5 milligrams lost an average of 35 pounds (16 kilograms), and participants who took a dose of 10 milligrams lost an average of 49 pounds (22 kilograms), 15 milligrams. Participants lost an average dose of 52 pounds (23.6 kilograms).
“Almost 40% of individuals have lost a quarter of their weight,” said co-author Dr. Ania Justrebov, co-director of the Yale University Weight Management Center in a media briefing.
“The data were very impressive,” said Dr. Robert Gabey, Chief Health Officer of the American Diabetes Association, who spoke to CNN from ADA’s 82nd Scientific Session in New Orleans, where the findings were published. Told.
“The weight loss they gained in this study was even greater than that seen in previous studies of diabetics,” said Gabey, who was not involved in the study.
“The middle range of people’s weight loss in this new study was £ 49-there are plenty of £ 49,” he said. “This is the range of weight loss we think is usually possible only by surgery.”
“This is not uncommon,” he said. “The effects of previous weight loss medications aren’t very effective for diabetics, and honestly I don’t know the exact reason.”
However, the impact of tyrzepatide on diabetics remains “serious,” “providing far more than the other tools we had,” Gabey said.
Self-injection dose
A new study shows weekly tyrzepatide in more than 2,500 people without diabetes who have a body mass index (BMI) greater than 30 or a BMI greater than 27 and have at least one weight-related health condition such as high blood pressure. Tested for injection. , High cholesterol or cardiovascular disease. A BMI of 25 or higher, which is a measure of a person’s height-to-weight ratio, is considered overweight in adults.
At the beginning of the study, participants weighed 231 pounds (104.8 kilograms) and had an average BMI of 38.
Adults in this study used a “small pen-like device with a small small needle” to inject tyrzepatide or placebo once a week, Gabey said. “Stab wounds from that needle are less painful than, for example, a person who stabs a finger to measure blood sugar.”
Researchers also received counseling sessions to help them maintain a healthy diet with a daily lack of 500 calories and at least 150 minutes of physical activity each week. It certainly helped, but it doesn’t explain the magnitude of weight loss seen in the study, Gabey said.
“The weight loss you see when people exercise and change their calorie intake is on the order of 5% to 7%,” he said. “This study showed much greater weight loss than we can imagine due to lifestyle changes.”
The most common side effects reported were nausea, diarrhea and constipation. 2.6% to 7.1% of participants discontinued treatment due to adverse events.
Mounjaro displays a box warning about thyroid tumors. Do not use if you have a family history of a particular thyroid disease.
“Obesity should be treated like any other chronic disease-with an effective and safe approach to targeting (the cause of) the underlying disorder … and these results are exactly what Tirzepatide does. “We are emphasizing that there may be,” said Justrebov of the Yale University Weight Management Center in a news release from the American Diabetes Society.
“These results are important steps in potentially expanding effective treatment options for obese people.”
..
